Recent advances in vascular gene transfer have shown potential new treatment modalities
for cardiovascular disease, particularly in the treatment of vascular restenosis. The antisense …

One of the potential clinical applications of antisense therapy is the prevention or treatment
of restenosis following coronary interventions. Inhibition of several cellular proto-oncogenes …

Objectives: This study was designed to determine whether antisense oligodeoxynucleotides
(ODN) directed against the nuclear proto-oncogene c-myc could inhibit restenosis when …

Percutaneous transluminal angioplasty is now a well-established and frequently performed
procedure that has an initial success rate in reestablishing arterial patency of> 95%. 1 2 …

The pace of recent developments in molecular biology has been unparalleled in modem
medical history. Therapeutic manipulation of gene expression, considered to be in the …

A primary pathologic response to vascular injury is the proliferation and migration of
vascular smooth muscle cells and the development of neointimal lesions. An increasing …

Antisense oligodeoxynucleotides, by inhibiting the expression of specific gene products,
provide a theoretically simple and precise tool for identifying mechanisms responsible for …

Objectives: We evaluated the long-term influence of intramural delivery of advanced c-myc
neutrally charged antisense oligonucleotides (Resten-NG) on neointimal hyperplasia after …

Restenosis after percutaneous transluminal coronary angioplasty (PTCA) and coronary
stenting remains a major clinical problem. Vascular smooth muscle cell (SMC) proliferation …

Background Antisense oligonucleotides have been used in animals to inhibit the
accumulation of vascular smooth muscle cells (VSMCs) after arterial injury. This has raised …